Last reviewed · How we verify
NCT04398498
Molecular Biomarkers in Renal Transplantation Via TruGraf® Test
trial testing Diagnostic Test: TruGraf® Testing in Kidney Transplant Rejection in 50 participants. Status unknown.
30 November 2022
Quick facts
| Lead sponsor | Transplant Genomics, Inc. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 13 April 2020 |
| Primary completion | 30 November 2022 |
| Estimated completion | 30 November 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Diagnostic Test: TruGraf® Testing
Conditions studied
- Kidney Transplant Rejection — all drugs for Kidney Transplant Rejection →
Sponsor
Transplant Genomics, Inc. — full company profile →
Who can join
18 and older, any sex, with Kidney Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The TruGraf® test is a non-invasive blood test that measures molecular gene expression profiles associated with clinical conditions previously only diagnosed by biopsy in kidney transplant recipients. The results of the TruGraf test provide additional information about the adequacy of immunosuppression and may be used to support decisions in patient management.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04398498
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Transplant Rejection
Currently open trials in the same condition.
- NCT07412470 — A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantati · Phase 2, PHASE3 · recruiting
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
- NCT06564649 — PROACT Pilot Trial · active not recruiting
- NCT07006532 — Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab · NA · recruiting
- NCT07275541 — Platelet Aggregation in the Diagnosis of Acute Graft Rejection · recruiting
Other Transplant Genomics, Inc. trials
Trials by the same sponsor.
- NCT07393594 — ID-ENTITY Trial- Evaluating Serial T-ID Monitoring · not yet recruiting
- NCT07231328 — PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients) · not yet recruiting
- NCT05335538 — TruGraf and TRAC In Pediatrics Study · unknown
- NCT04670926 — Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test · NA · unknown
- NCT04267016 — Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04398498 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Transplant Genomics, Inc.
- Last refreshed: 19 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04398498.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing